Lysosomal storage diseases (LSDs) are a group of genetic disorders, resulting from deficiencies of lysosomal enzyme. Genotype-phenotype correlation is essential for timely and proper treatment allocation. Recently, by integrating prediction outcomes of 7 bioinformatics tools, we developed a SAAMP algorithm to predict the impact of individual amino-acid substitution. To optimize this approach, we evaluated the performance of these bioinformatics tools in a broad array of genes. PolyPhen and PROVEAN had the best performances, while SNP&GOs, PAN-THER and I-Mutant had the worst performances. Therefore, SAAMP 2.0 was developed by excluding 3 tools with worst performance, yielding a sensitivity of 94% and a specificity of 90%. To generalize the guideline to proteins without known structures, we built the threedimensional model of iduronate-2-sulfatase by homology modeling. Further, we investigated
| INTRODUCTION
Lysosomal storage diseases (LSDs) represent a group of approximately 70 inborn errors of metabolism, and the total incidence is approximately from 1:5000 to 1:10,000.
1,2 LSDs result from accumulation of specific macromolecules, including lipids, glycoproteins and glycosaminoglycans inside the organelles, for example, endosome, autophagosome and lysosome. Accumulation of these macromolecules leads to tissue damage in multiple organs and subsequent disease-specific symptoms. 3 The age of clinical onset and spectrum of symptoms exhibited among different LSDs and subtypes of 1 LSD vary. It depends on the degree of protein function affected by specific mutations, the biochemistry of the storage materials, as well as the cell types where storage occurs.
Diagnosis of LSDs is an often long and burdensome odyssey, 4 which usually includes quantification of macromolecules excreted in urine, enzyme assay with leukocytes (or cultured skin fibroblasts), mutation analysis and symptoms-based judgment. An alternative approach is newborn screening (NBS) program, which shortens the diagnostic process. Early detection by NBS allows for early initiation of disease-modifying treatment which is essential for optimal treatment efficacy. However, NBS usually leads to the identification of individuals with low enzyme activity with previously unreported genetic variants of unknown significance. 5 Therefore, decisions on treatment initiation can be complicated in pre-symptomatic patients, and a robust phenotypic prediction is essential.
To this end, we utilized the bioinformatics tools to analyze mutations in the IDUA gene and established a guideline for predicting genotype-phenotype correlation of MPS I disease ( Figure 1 ). 6 More importantly, a SAAMP algorithm was established to predict the phenotype of amino-acid changes by integrating prediction results of these 7 bioinformatics tools. When tested in the IDUA gene, the SAAMP algorithm yielded a sensitivity of 94% and a specificity of 80%. This model represents a readily accessible and reliable method to predict phenotype of a variety of monogenic diseases.
However, as shown in Figure 1 
| MATERIALS AND METHODS

| Dataset
Known disease-associated mutations were obtained from The Human
Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php).
The benign polymorphisms were obtained from the NCBI dbSNP (http://www.ncbi.nlm.nih.gov/snp/) and from the previous literature. 
| Predicting functional context of missense mutation
A total of 7 bioinformatics tools were used as previously described. structure model by using replica-exchanged Monte Carlo simulations. 7 The quality of predicted structure is estimated by I-TASSER in the form of confidence score (C-score). The C-score ranges from 
| SAAMP algorithm 2.0
Due to the inherent false positives and negatives associated with each tool, combing different tools is expected to remarkably increase the accuracy. In our previous study, 6 by integrating outcomes of these 7 tools (SIFT, PolyPhen, PROVEAN, PHD-SNP, PANTHER, SNPs&GO and I-Mutant), a SAAMP algorithm with a pathogenic index (PI) was developed. PI is defined as ratio of "damaging" predictions from these 7 tools (ranging from 0 to 1), where the higher the PI is, the more pathogenic the mutation is. The cut-off value was set at 0.43. When PI was ≥0.43 (≥3 "damaging" predictions), the mutation was defined as "pathogenic," otherwise "benign." When tested in the IDUA gene, a sensitivity of 94% and a specificity of 80% was achieved, which was better than any individual tool. In this study, by testing each tool in a total of 13 genes associated with LSDs Since these bioinformatics tools are not specifically designed for an individual lysosomal disease, they cannot predict the phenotype severity (disease subtypes). Nonetheless, we investigated the possibility of using the SAAMP 2.0 algorithm to predict phenotype severity.
Interestingly, there was a weak positive correlation (r 2 = .043, P = .02)
between PI and phenotype severity in MPS II disease (IDS gene). However, there were no such correlations in the IDUA (P = .16) or GLB1 (P= .49) genes. When combining the results of all 3 genes, no significant correlation was observed (P = .15). This discrepancy between IDS and the other 2 genes may be explained by the simplicity of genotypephenotype correlation in the IDS gene. The IDS gene is involved in an X-linked disease associated with only 2 subtypes (attenuated and severe). In sharp contrast, IDUA and GLB1 are involved in autosomal recessive diseases associated with 3 or more subtypes and many cases of compound heterogeneity. In summary, the PI may have the potential to be used as a predictor in diseases with simple genotypephenotype correlation, but should be further assessed.
| Phenotype severity of missense mutations in the GLB1 gene
Q4 is about whether we can deduce phenotype severity (disease subtypes) from the previous literature in more complicated scenarios. or β,1-3-linked galactose residues from GM1 gangliosides and keratan sulfate-derived oligosaccharides. 8 We analyzed the phenotypes (based on clinical/biochemical results) of patients in the original reports and summarized phenotype severity of each mutation. The lack of enough information and consensus of phenotype severity makes it difficult to comprehensively evaluate reliability of the original reports. Accordingly, the severity predictions with relatively low reliability is highlighted with "*" in Table 1 . Similar analyses have been conducted with other genes associated with LSDs (data not shown).
To gain further insights into the impact of the mutations, we extracted the structure of β-Gal from the PDB database (ID 3wf2) 9 and conducted structural analyses. β-Gal forms a homodimer, and it has 3 domains: β domain 1 (amino acid 397-514), β domain 2 (545-
647) and TIM barrel domain (49-359). TIM barrel domain is a catalytic
domain with the active site in the core. Based on the results in Table 1 , mutations responsible for a certain disease subtype were scattered through all domains. It was shown that the active site is comprised of Tyr83, Ile126, Cys127, Ala128, Glu129, Asp187, Glu188, Glu268, Tyr270, Trp273, Leu274, Tyr306, Tyr331 and Tyr333. 10 Out of these amino acids, Glu188 and Glu268 were responsible for the catalytic reaction, while Tyr83, Ala128, Glu129, proteins by SWISS-MODEL, using the native structure as the template. SWISS-MODEL is a fully automated protein structure homology modeling server. 11 Superimposition of native protein and mutant was investigated with Swiss-PDB viewer ( Figure 3A ). Root mean square deviation (RMSD) values between the native and each mutant structures are <0.5 Å, indicating a minor structural change due to these mutations. Further, Project Hope revealed the 3D structure of the mutants, and described the physiochemical properties of specific mutations. p.Tyr270Asp, a mutation at a 100% conserved site, was found to cause infantile GM1 gangliosidosis. p.Tyr270Asp introduced a charge in the buried residue, which could lead to protein-folding problems ( Figure 3C ). This mutation could also cause loss of hydrophobic interaction and empty space within the core of the protein.
More importantly, Tyr270 was located in the active site, and also interacted with Glu268, which was the catalytic nucleophile. Therefore, p.Tyr270Asp could affect the catalytic activity of Glu268, and thus cause a complete loss of enzyme activity. p.Cys127Tyr, another mutation at a 100% conserved amino acid within the active site, was found to cause juvenile GM1 gangliosidosis. The mutant residue (tyrosine) was bigger than the wild-type residue (cysteine). Since the cysteine residue was buried in the core of the protein, the mutant residue was bigger and probably would not fit. This mutation would 
| Homology modeling to build 3D structure models
Several 3D models of the IDS protein have been proposed, 12-16 but its crystal structure has not been solved yet. To establish a readily accessible and easy-to-use homology modeling method, we 4 | DISCUSSION
| Updated guideline
Collectively, by answering the 5 questions listed in Figure 1 , the protocol for phenotype prediction proposed was optimized and might be generalized to all monogenic diseases. Therefore, a revised protocol for phenotype prediction was proposed and illustrated in Figure 5 .
When a mutation is identified, (1) if it is a known disease-associated mutation, refer to original publications to deduce phenotype severity;
(2) if not, conduct the in silico analysis of novel mutations. SAAMP 2.0 has been shown to accurately and reliably predict phenotype based on genotype in a variety of genes, and may be applied in most monogenic diseases. Notably, the major limitation of SAAMP is that it can only predict whether a mutation will be "pathogenic" or "benign," but cannot predict specific subtypes (eg, Hurler, Hurler-Scheie, or Scheie in MPS I disease). Further refinement is necessary to improve its ability in predicting disease subtypes. In a compound heterozygote with 1 mutation on each allele, SAAMP algorithm can be used to predict phenotype of each mutation first. Then, valuable inferences about the phenotype of patients can be made, which are essential for early diagnosis and proper treatment allocation. For instance, if both mutations are predicted to be "pathogenic," then the patient phenotype is expected to be "disease." If only 1 mutation is predicted to be "pathogenic," then the patient phenotype is expected to be "normal" (autosomal recessive) or "disease" (autosomal dominant). If both mutations are predicted to be "benign,"then the phenotype is expected to be "normal." Further confirmation should be conducted through biochemical and/or clinical analyses. Future refinements of this protocol can be conducted by investigating amino-acid substitutions that can affect transcriptional and splicing regulation.
For instance, ESEfinder (rulai.cshl.edu/ESE) 17 and FAS-ESS (genes.mit.
edu/fas-ess/) 18 can predict the impact of mutations on splicing.
| Hypothesis about predicting type I, II, III or MDB
Generally speaking, the higher the residual enzyme activity is, the less severe the phenotype is. However, the residual enzyme activity gene. This may result from the use of artificial substrates in the enzyme assay, which cannot accurately replicate enzyme reaction with natural substrates under physiological conditions. Also, it is likely that modifier genes can alter enzyme activity and thereby disease severity. 8 Based on the results presented in this study and previous findings, we developed a theory to explain the relationship between mutations and specific disease subtypes. Infantile GM1 (<1% of wildtype enzyme activity) represents almost complete loss of activities degrading all substrates, including GM1 gangliosides and keratan sulfate. This is supported by the fact that in addition to neurological disorders, infantile has significant skeletal abnormalities 19 and accumulation of keratan sulfate. 20 Additional evidence is that most nonsense mutations lead to infantile GM1 gangliosidosis. Juvenile (1%-10%) and adult GM1 (5%-10%) represent reduced activities degrading GM1 gangliosides only. These mutations mainly affect the ligand binding of GM1 gangliosides or association of activator protein (eg, saposin B). MDB (2%-12%) represents reduced activities degrading keratan sulfate only. These mutations mainly affect the ligand binding of keratan sulfate, which is thought to be favored over GM1 gangliosides. 8 For similar reasons, mutations affecting the stability of the proteins have more impact on degradation of GM1 gangliosides than keratan sulfate. It also explains why the worldwide incidence of MDB was less compared with GM1 gangliosidosis. 21 Further, there is an alternative spliced product of GLB1 gene, elastin/laminin-binding protein (EBP). Loss of EBP function may be responsible for cardiomyopathy in GM1 gangliosidosis. 22 Therefore, if the mutations occur in the common region between EBP and β-gal, there might be a loss of EBP function and cardiomyopathy, which warrants extra attention.
